Clinical Trial Update: PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating belinostat (PXD101) in combination with bortezomib in adults with advanced solid tumors or lymphomas has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• BELEODAQ (BELINOSTAT)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma | Phase 1 | Status: COMPLETED